Publications by authors named "Maria Jose Forner Giner"

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency characterized by decreased immunoglobulins and recurrent infections. Its aetiology remains unknown, and some patients present with severe non-infectious autoimmune or inflammatory complications with elevated associated morbimortality. Recently, intestinal dysbiosis has been proposed as a driver of immune dysregulation.

View Article and Find Full Text PDF

Background: A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of the Phase IIb HH-2, where the immunogenicity and safety of a heterologous booster with PHH-1V is assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration.

Methods: The HH-2 study is an ongoing multicentre, randomised, active-controlled, double-blind, non-inferiority Phase IIb trial, where participants 18 years or older who had received two doses of BNT162b2 were randomly assigned in a 2:1 ratio to receive a booster dose of vaccine-either heterologous (PHH-1V group) or homologous (BNT162b2 group)-in 10 centres in Spain.

View Article and Find Full Text PDF
Article Synopsis
  • Common Variable Immunodeficiency (CVID) is a diverse group of primary immunodeficiency disorders that presents a wide range of clinical challenges, including significant non-infectious health issues among patients.
  • A nationwide study in Spain over three years examined 250 CVID patients, revealing a diagnostic delay of about 10 years, with infectious complications initially predominant, though non-infectious lung diseases and immune disorders were more common overall.
  • The study highlighted a high prevalence of associated conditions, such as benign lymphoproliferation and cancers, indicating a need for further research to develop better treatment strategies and improve the quality of life for those affected by CVID.
View Article and Find Full Text PDF

Background: Granulomatous-lymphocytic interstitial lung disease (GLILD) is a distinct clinic-radio-pathological interstitial lung disease (ILD) that develops in 9% to 30% of patients with common variable immunodeficiency (CVID). Often related to extrapulmonary dysimmune disorders, it is associated with long-term lung damage and poorer clinical outcomes. The aim of this study was to explore the potential use of the integration between clinical parameters, laboratory variables, and developed CT scan scoring systems to improve the diagnostic accuracy of non-invasive tools.

View Article and Find Full Text PDF